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a  b  s  t  r  a  c  t
Inulin  is  a ﬂexible  oligosaccharide  which  has  been  used  primarily  in food  for  decades.  Recently  new
applications  in  the  pharmaceutical  arena  were  described.  In  a  previous  review  (Mensink  et  al.  (2015).
Carbohydrate  Polymers,  130, 405)  we  described  the  physicochemical  characteristics  of  inulin,  character-
istics which  make  inulin  a highly  versatile  substance.  Here,  we  review  its pharmaceutical  applications.
Applications  of  inulin  that  are  addressed  are  stabilization  of  proteins,  modiﬁed  drug  delivery  (dissolu-
tion  rate  enhancement  and  drug  targeting),  and  lastly  physiological  and  disease-modifying  effects  ofeywords:
ructan
nhydrobiosis
accines
tabilizer
ormulation
xcipient
inulin.  Further  uses  of  inulin  include  colon  speciﬁc  drug  administration  and  stabilizing  and  adjuvating
vaccine  formulations.  Overall,  the  uses  of  inulin  in the  pharmaceutical  area  are very  diverse and  research
is still  continuing,  particularly  with  chemically  modiﬁed  inulins.  It is therefore  likely  that even  more
applications  will  be found  for  this  ﬂexible  oligosaccharide.
©  2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Inulin is a fructan-type oligosaccharide that can be found in a
ide range of plants (Apolinário et al., 2014). It was discovered in
he 19th century (Fluckiger & Hanbury, 1879) and since then its
haracteristics has been investigated extensively. Most commer-
ially available inulin is extracted from chicory root, which contains
 relatively high concentration of this carbohydrate (Franck, 2002).
nulin has proven to be a versatile substance with a large number
f different applications mainly in food and pharma. In a previ-
us review, we addressed the physicochemical properties of inulin
hat make it such a widely applicable compound (Mensink, Frijlink,
an der Voort Maarschalk, & Hinrichs, 2015). Processing history
nd degree of polymerization have a large impact on the physico-
hemical behavior of inulin. As physicochemical behavior governs
unctionality for different applications, these characteristics should
e taken into account when using inulin.Some examples of saccharides frequently used as excipient in
harma are glucose, sucrose, trehalose, lactose, dextran and cellu-
ose (Mensink et al., 2015). Inulin differs from these saccharides
∗ Corresponding author. Tel.: +31 50 363 2398; fax: +31 50 363 2500.
E-mail address: W.L.J.Hinrichs@rug.nl (W.L.J. Hinrichs).
ttp://dx.doi.org/10.1016/j.carbpol.2015.08.022
144-8617/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article
.0/).in molecular weight and/or the type of glyosidic bond between
monomers. Inulin has a higher molecular weight than mono- and
disaccharides, with that it has a higher glass transition and melt-
ing temperature, and is more viscous when dissolved. The higher
molecular weight also correlates with a lower solubility. Compared
to other oligo- and polysaccharides, inulin has a high molecu-
lar ﬂexibility because of its (2 → 1) linked-d-fructosyl backbone.
Therefore inulin has relatively low glass transition and melting
temperatures compared to other oligo- and polysaccharides. These
characteristics can be both advantageous and disadvantageous
depending on the application at hand. Unlike most of the other
mentioned saccharides, inulin is not metabolized by humans. This
allows for unique applications such as determination of kidney
function and colonic targeting, which makes use of metabolization
by microbiota present in the colon. Reducing groups of saccharides
are undesired for many pharmaceutical applications. When pres-
ence of reducing groups is a concern, inulin is more suitable as
an excipient than for example glucose and lactose (Mensink et al.,
2015; Tonnis et al., 2015).
Over the past decades, more and more research on food and
pharmaceutical applications of inulin has been published. The
approval of the Generally Recognized As Safe (GRAS) status of
inulin by the United States Food and Drug Administration in 2002
seems to have provided a boost to research into applications
 under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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f inulin (Kruger, 2002). As inulin’s food applications have been
eviewed before we will not discuss them here (Mensink et al.,
015). To our knowledge, only one review has been published in
hich pharmaceutical applications of inulin are addressed amongst
ther topics (Barclay, Ginic-Markovic, Cooper, & Petrovsky, 2010).
n this manuscript, an overview will be given of the current
harmaceutical applications of inulin in the light of its physico-
hemical characteristics. Applications which will be addressed are
tabilization of proteins, modiﬁed drug delivery (dissolution rate
nhancement and drug targeting), and physiological and disease-
odifying effects of inulin.
. Pharmaceutical applications
.1. Stabilization
.1.1. Anhydrobiosis
In nature, inulin has been associated with drought protection
n several plants, with increased levels of inulins found in stress
esilient plants (Livingston, Hincha, & Heyer, 2007; Matvieieva
t al., 2013). Membrane stabilization is believed to be an impor-
ant part of the drought protection of inulin (Livingston et al.,
007). Vereyken, Albert van Kuik, Evers, Rijken, and de Kruijff
2003a), Vereyken, Chupin, Demel, Smeekens, and De Kruijff
2001), Vereyken, Chupin, Hoekstra, Smeekens, and de Kruijff
2003b) and Vereyken et al. (2003c) have published several papers
n the mechanism of stabilization of fructans on membranes.
hey investigated the effects of inulin on model systems, such as:
hospholipid monolayers, bilayers and liposomes in states varying
rom dry to completely hydrated. Fructans (inulin- and levan-type)
ere found to increase lamellar repeat distance and reduce vesi-
le fusion during air drying, indicating they were present between
he lipid bilayers (Vereyken et al., 2003c). Fructans insert between
he headgroups of several glyco- and phospholipids even if the
ipid packing is very tight (Vereyken et al., 2001, 2003a,b). Fruc-
an immobilized the lipid headgroups through direct interaction,
ut increased mobility of the acyl chains because the insertion of
ructan caused them to be spaced further apart, in turn leading
o a lower order–disorder phase transition temperature (Vereyken
t al., 2003b). Additionally, fructan reduced the accessibility of the
embranes, indicative of some form of coating of the membrane
Vereyken et al., 2001).
The effect of fructans on the membranes was much stronger
han that of other polysaccharides such as dextran, which was
xplained by inulin’s more hydrophobic character (Vereyken et al.,
001). Inulin showed more interaction with the headgroups than
evan-type fructan (Vereyken et al., 2003a). This is probably because
nulin inserts more deeply into the membrane compared to levan
Vereyken et al., 2003b). Increasing molecular weight of inulin was
ound to correlate with stronger interactions with the membranes
Vereyken et al., 2003a). Levan-type fructans perform worse than
nulin-type fructans despite the fact that they are much larger.
pparently, some other trait of inulin must be the reason for its suc-
ess. The ﬂexibility of inulin’s molecular backbone, conformation of
he backbone as well as hydrophobicity were suggested as expla-
ations for inulin’s effects on these membranes (Vereyken et al.,
003a,c) Additionally, inulin’s furanose groups are also smaller and
ore ﬂexible compared to pyranose groups found in dextrans.
Hincha et al. also investigated membrane stabilization by
ligosaccharides including inulin using liposomes as model sys-
ems (Hincha, Hellwege, Heyer, & Crowe, 2000; Hincha, Zuther,
ellwege, & Heyer, 2002; Hincha, Zuther, & Heyer, 2003; Livingston
t al., 2007). During freeze-drying inulin stabilized large unilamel-
ar vesicles of egg phosphatidylcholine, whilst hydroxyethylstarsch
HES) did not stabilize them at all. A combination of inulin andolymers 134 (2015) 418–428 419
glucose was especially effective (Hincha et al., 2000). Based on ﬁnd-
ings with rafﬁnose-family oligosaccharides, it was concluded that
a higher degree of polymerization (DP) provides increased pro-
tection of liposomes against fusion at elevated temperatures and
against leakage after rehydration, because of the higher glass tran-
sition temperature (Tg) of longer chain oligosaccharides (Hincha
et al., 2003). A larger chain length resulted in better membrane sta-
bility during air drying when inulin-type fructans were used, but
not when glucans were used (Hincha et al., 2002). Glucans were
however increasingly effective at reducing membrane fusion with
increasing chain length, contrary to inulin (Hincha et al., 2002). The
limited solubility of larger inulin (DP > 10) caused it to precipitate
during the used slow air-drying and prevented it from stabilizing
the liposomes (Livingston et al., 2007). In agreement with the ﬁnd-
ings of Vereyken et al. discussed above, Hincha et al. (2000, 2002)
also found a direct interaction of inulin with the phospholipid in
the dry state and a reduction of the gel to liquid-crystalline phase
transition temperature.
Livingston et al. (2007) have provided an in-depth review on
abiotic stress tolerance in plants by fructans. It shortly describes
current, more general theories on how (oligo)saccharides stabi-
lize membranes, mainly the vitriﬁcation theory and the water
replacement theory. The water replacement theory explains how
sugars stabilize membranes by replacing the hydrogen bonds of
water with the membrane during drying and thereby inserting into
the lipid bilayer (Vereyken et al., 2003b). Overall, it seems that
inulin’s characteristics, the structural ﬂexibility of the backbone
and furanose groups, conformation, and hydrophobic-hydrophilic
balance allow it to interact with the membranes better than other
oligosaccharides as described above. Inulin’s ﬂexibility in particular
allows it to overcome the steric hindrance which usually inhibits
sugar–membrane interactions (Livingston et al., 2007; Vereyken
et al., 2003c).
The vitriﬁcation theory states that sugars form glasses instead
of crystals during drying. The viscosity of a glass is extremely high,
resulting in practically no diffusion and restricted molecular mobil-
ity of the membranes. A kinetically stable glass is the result. The
glass should remain amorphous, as crystallization would lead to a
loss of protein–sugar interactions. Clearly, a higher Tg then corre-
lates with better stabilization (Livingston et al., 2007). Therefore,
vitriﬁcation alone cannot explain the stabilizing effect of fructan
(Crowe, Carpenter, & Crowe, 1998; Crowe, Leslie, & Crowe, 1994;
Crowe, Oliver, Hoekstra, & Crowe, 1997), as other oligosaccharides
with even higher Tgs, such as dextran and hydroxyethyl starch,
did not provide better stabilization. Both vitriﬁcation and water
replacement are needed for stabilization (Crowe et al., 1998). Inulin
is unique in its ability to vitrify as an oligosaccharide, whilst main-
taining a good interaction with the membrane as if it was a smaller
saccharide, thus combining requirements for both the vitriﬁcation
and water replacement theories.
2.1.2. Protein stabilization
The mechanisms behind membrane stabilization in nature and
protein stabilization in the pharmaceutical arena are very sim-
ilar, with the vitriﬁcation theory and water-replacement theory
also being applicable to protein stabilization (Crowe et al., 1998;
Crowe, Hoekstra, & Crowe, 1992). Recently, the role of these two
different mechanisms under different conditions was investigated
(Grasmeijer, Stankovic, de Waard, Frijlink, & Hinrichs, 2013). It was
concluded that if the Tg of a sample is at least 10–20 ◦C above storage
temperature, water replacement is the predominant mechanism of
stabilization. However if the Tg is lower, vitriﬁcation limits stabil-
ity (Grasmeijer et al., 2013). In other words, if the Tg is high enough
to immobilize the protein, the amount of interaction between the
sugar and the protein determines its stability, yet if the Tg is too
low, the (lack of) immobilization becomes the limiting factor.
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Other physico-chemical characteristics of sugars required for
ood stabilization are low hygroscopicity, low crystallization
ate and little or no reducing groups. For freeze-drying a high
g of the maximum freeze-concentrated solution (Tg’) is also
esired. Compared to trehalose, which is a frequently used pro-
ein stabilizer, inulin has similar hygroscopicity, it crystalizes
ess rapidly and the longer chain inulins have higher Tg and
g’ values (Mensink et al., 2015). Additionally, higher molec-
lar weight inulin has fewer reducing groups, a higher glass
ransition temperature and with that a lower tendency to crys-
allize for example when exposed to ambient moisture. This
eing given, it is not surprising that inulin was  shown to be a
ood stabilizer of proteins under various conditions and stresses.
nulin has been successfully used to stabilize proteins during
pray-drying (Grasmeijer et al., 2013; Haj-Ahmad, Elkordy, Chaw,
 Moore, 2013; Saluja et al., 2010), freeze-drying (lyophiliza-
ion) (Amorij et al., 2007b; Hinrichs, Prinsen, & Frijlink, 2001;
odríguez Furlán, Lecot, Pérez Padilla, Campderrós, & Zaritzky,
011; Rodríguez Furlán, Padilla, & Campderrós, 2010; Rodriguez
urlán, Pérez Padilla, & Campderros, 2011; Tonnis et al., 2015)
nd spray-freeze drying (Amorij et al., 2007b; Saluja et al., 2010;
ahjudi et al., 2013). However, inulin does have some reduc-
ng groups, limiting its applicability to some extent (Zijlstra
t al., 2009a). The number of reducing groups is dependent
n processing and DP and is generally limited (Mensink et al.,
015).
Inulin, trehalose and dextran have been identiﬁed as suitable
ryo- and lyoprotectants for the major constituent of inﬂuenza sub-
nit vaccine, i.e. haemagglutinin (HA), meaning they all stabilized
A during freezing and freeze-drying (Amorij et al., 2007a). Dur-
ng storage of 4 different model proteins after lyophilization, inulin
as a better protein stabilizer than a similar-sized dextran (Tonnis
t al., 2015). Storage temperature was well below the Tg of the
ormulations to allow for optimal vitriﬁcation. Water-replacement
as therefore considered to be dominating protein stability. It was
uggested that inulin encountered less steric hindrance than dex-
ran when interacting with the protein, because of inulin’s higher
olecular ﬂexibility. Lyophilization of alkaline phosphatase with-
ut stabilizer reduced its activity to around 5%, but when either
nulin, trehalose or glucose was added, full activity was maintained
Hinrichs et al., 2001). When added to bovine plasma protein, inulin
lso reduced denaturation during freeze-drying similar to sucrose
nd glucose, with an optimal concentration of 10% w/v (Rodríguez
urlán et al., 2010, 2011).
During spray-freeze-drying, spraying a solution into liquid
itrogen followed by freeze-drying, HA stabilized with inulin in
epes buffer was  not structurally altered and it did not lose its
ntigenetic properties (Amorij et al., 2007b; Saluja et al., 2010).
hen PvdQ, acyl-homoserine-lactone (AHL) acylase, was spray-
reeze-dried, mannitol, trehalose and inulin all fully maintained its
ctivity (Wahjudi et al., 2013). Inulin has also been applied as a pro-
ein stabilizer during hot-melt extrusion, in which a polymer based
roduct for the controlled release of protein is created. As lysozyme
s a relatively thermostable protein (Pfeil & Privalov, 1976), no
egradation was found during extrusion at 55 ◦C. It was  however
uggested that for a more labile protein, inulin could also provide
rotection to the heat stress induced by this process (Stankovic´
t al., 2013).
The main goal of the various processes described above is to
chieve a product that is stable over time. Table 1 provides an
verview of reports on inulin’s stabilizing effect on dried pro-
eins during storage under various conditions. Tonnis et al. (2015)
eported degradation kinetics of their 4 model proteins during stor-
ge (60 ◦C, <10% RH, 28 days), but not the remaining activity after
torage. Their results are therefore not included in this table, the
eader is directed to that article for further information.olymers 134 (2015) 418–428
At room temperature inulin proved to be an equally good or
better stabilizer than other saccharides. With increasing relative
humidity, inulins with a higher DP perform better. This is likely
because those inulins have a higher intrinsic glass transition tem-
perature and can thus absorb more water before this lowers the
Tg of the mixture to below the storage temperature. The rela-
tively small inulin with DP 6, also called oligofructose, caused a
loss of activity of around 50% in alkaline phosphatase. Degrada-
tion that may  be induced by the relatively high amount of reducing
groups in that particular inulin sample. This level of degradation
was not found with the other, larger inulins tested (Hinrichs et al.,
2001). When lyophilized alkaline phosphatase formulations with
trehalose were compressed into tablets, the very brief exposure to
atmospheric moisture and compacting forces resulted in formation
of trehalose anhydrate crystals, leading to a complete loss of activity
of the incorporated protein within 1 week of storage at 60 ◦C/0%RH.
In contrast, inulin remained amorphous and maintained 75% activ-
ity of the protein after 3 months of storage at 60 ◦C/0%RH. In fact,
inulin did not even crystallize when stored at 60 ◦C, 33% RH for two
days (Eriksson et al., 2002). PvdQ spray freeze dried with mannitol
stored at 55 ◦C also resulted in crystallization of the sugar, lead-
ing to a complete loss of activity (Wahjudi et al., 2013). Inulin and
dextran were unable to maintain activity of air-dried samples of
restriction enzyme PstI stored at 37 ◦C (Colac¸ o, Sen, Thangavelu,
Pinder, & Roser, 1992). It is most likely that limited solubility of
inulin caused it to precipitate during this slow drying process, in
turn preventing it from stabilizing the protein as was also seen
with air-dried liposomes (Livingston et al., 2007). Unfortunately,
the authors did not report the DP of the inulin, which inﬂuences its
solubility (Colac¸ o et al., 1992).
At elevated temperatures, the stabilizing capacities of different
saccharides varies. As mentioned above, if vitriﬁcation is sufﬁ-
ciently achieved, the stabilizer with most interactions with the
protein is likely to stabilize best. Oligosaccharides, however, are
more sterically hindered than smaller mono- or disaccharides,
reducing their interactions with the protein (Tonnis et al., 2015).
Inulin’s molecular ﬂexibility is able to compensate this to some
extent, unlike the more molecularly rigid dextran (Amorij et al.,
2007a; Tonnis et al., 2015). Thus depending on the storage tem-
perature and the Tg of the sample, a longer chain length of the
oligosaccharide (resulting in a higher Tg) could be beneﬁcial if vitri-
ﬁcation is lacking, yet it could also have the opposite effect if more
protein–sugar interaction is needed. As mentioned inulin has a
small amount of reducing groups, meaning some protein degrada-
tion because of the Maillard reaction might occur. Yet even under
extreme storage conditions (85 ◦C/0%RH/42days) this only played
a minor role in protein stability of rhDNase, a protein that is sensi-
tive to this type of degradation (Zijlstra et al., 2009a). In summary,
inulin is a good stabilizer of proteins in the dry state, and depend-
ing on the formulation and storage conditions it can be better than
smaller sugars.
2.1.3. Other stabilization
Apart from membranes and proteins, inulin has also been used
to stabilize several pharmaceutically relevant systems. For exam-
ple, (PEGylated) liposomes, polyethylenimine based polyplexes,
lipoplexes (Hinrichs et al., 2006; Hinrichs, Sanders, De Smedt,
Demeester, & Frijlink, 2005), polymersomes (Ayen & Kumar, 2012),
inﬂuenza virosomes with and without encapsulated plasmid DNA
(De Jonge et al., 2007), whole inactivated inﬂuenza virus (Audouy
et al., 2011), recombinant adenovirus (Chen et al., 2012), and 9-
tetrahydrocannbinol (THC) (Van Drooge et al., 2005; Van Drooge
et al., 2004b).
This variety of applications shows that under the appropri-
ate conditions inulin may  provide stabilization against chemical
degradation (e.g. THC) as well as against physical degradation
M.A. Mensink et al. / Carbohydrate Polymers 134 (2015) 418–428 421
Table  1
Overview of reported storage stabilities of proteins dried with inulin and other sugars. AP = alkaline phosphatase, DNase = recombinant human DNase, HA = haemagglutinin,
Lys  = lysozyme, PstI = restriction enzyme PstI, PvdQ = acyl-homoserine lactone acylase PvdQ; AD = air dried, FD = freeze-drying, SD = spray-drying, SFD = spray-freeze-drying,
T  = tableting, C = crystallization. n.r. = not reported.
Protein Protein:sugar
ratio (w/w)
Preparation Storage conditions Activity/potency loss after storage Article cited
T (◦C) RH (%) t (days) Stabilizer Loss*
PvdQ 1:100 SFD 20 <10% 28 Inulin DPn 23; trehalose None Wahjudi et al. (2013)
Mannitol Some
Liquid control (after 7 days) None
AP  1:9 FD 20 0 28 Inulin DPn 6**,14,23 None Hinrichs et al. (2001)
Glucose, trehalose None
No stabilizer Complete
AP  1:19 FD 20 0 105 Inulin DPn 23, trehalose None Eriksson et al. (2002)
HA 1:47 FD 20 0 182 Inulin DPn 6, DPn 14 <20% Amorij et al. (2007a)
Trehalose, dextran56kDa <20%
No stabilizer Complete
HA  1:200 SD,SFD 20 10 1085 Inulin DPn 23 None Saluja et al. (2010)
Liquid control 4 ◦C Complete
AP  1:9 FD 20 45 28 Inulin DPn 14,23; trehalose No Hinrichs et al. (2001)
Inulin DPn 6 ∼25%
Glucose ∼50%
No stabilizer Complete
AP  1:9 FD 20 60 28 Inulin DPn 14,23; trehalose None Hinrichs et al. (2001)
inulin DPn 6; glucose ∼50%
No stabilizer Complete
PstI  n.r. AD 37 n.r. 7 Trehalose None Colac¸ o et al. (1992)
Maltotriose 80–90%
Inulin; dextran *** Complete
HA  1:47 FD 45 11 28 Inulin DPn 14 38% Amorij et al. (2007a)
Inulin DPn 6 24%
Trehalose 23%
Dextran 56kDa 65%
No stabilizer 89%
HA  1:47 FD 45 11 182 Inulin DPn 6,14; dextran 56kDa; no stabilizer Complete Amorij et al. (2007a)
Trehalose 20%
PvdQ  1:100 SFD 55 <10% 28 Inulin DPn 23;trehalose No Wahjudi et al. (2013)
Mannitol Complete
Liquid control (after 7 days) Complete
AP  1:9 FD 60 0 6 Inulin DPn 14,23 ∼50% Hinrichs et al. (2001)
Inulin DPn 6; trehalose; glucose; no protectant Complete
AP  1:1–1:20 SD 60 ≤6% 19 Inulin DPn 23 30% Grasmeijer et al. (2013)
Trehalose 10%
DNAse 1:11 FD 60 0 42 Sucrose; trehalose; inulin DPn 14, 23 ∼20% Zijlstra et al. (2009a)
No protectant ∼65%
AP  1:19 FD 60 0 90 Inulin DPn 23 20% Eriksson et al. (2002)
Trehalose None
AP  1:19 FD+T 60 0 105 Inulin DPn 23 25% Eriksson et al. (2002)
Trehalose Complete
DNAse 1:11 FD 85 0 42 Trehalose ∼50% Zijlstra et al. (2009a)
Inulin DPn 14, DPn 23 ∼70%
Sucrose; protectant Complete
* If loss is listed as none, no signiﬁcant loss was detected.
(
a
a
a** Inulin DPn 6 can also be referred to as oligofructose.
*** Degree of polymerization/molecular weight was  not reported.e.g. lipoplexes). Inulin fully protected PEGylated lipoplexes against
ggregation during lyophilization and 3 months of storage there-
fter, whilst dextran did not (Hinrichs et al., 2005). Inulins were
lso preferred as stabilizer over dextran for various other types ofPEGylated nanoparticles due to their compatibility with PEG
(Hinrichs et al., 2006).
In preserving physicochemical characteristics of doxorubicin-
loaded (PEG)3-PLA nanopolymersomes during lyophilization,
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nulin was found to be superior over trehalose, sucrose, man-
itol, lactose, polyvinylpyrrolidone, and several other excipients
Ayen & Kumar, 2012). Inulin also fully preserved inﬂuenza viro-
omes during lyophilization. Compared to a liquid dispersion, the
owder had substantially prolonged preservation of potency and
n case of inﬂuenza virosomes with encapsulated plasmid DNA
ransfection activity (De Jonge et al., 2007). A combination of
annitol and inulin improved the therapeutic applicability of a
ecombinant adenovirus during freeze-drying and storage (Chen
t al., 2012). Lastly, incorporation of THC in an inulin matrix by
yophilization strongly increased its stability (Van Drooge et al.,
004b). Spray-freeze drying THC with inulin turned out to pro-
ide even better stabilization than freeze-drying, likely because
f the much faster cooling rate (Van Drooge et al., 2005). Inulin
ight therefore also be an interesting stabilizer for other unstable
rugs.
.2. Drug delivery
.2.1. Solution behavior alteration
.2.1.1. Solution rate enhancement. For oral drug administration,
rugs need to be dissolved before they can be absorbed by the
ntestinal membrane. Therefore, the bioavailability of drugs with
ow aqueous solubility (Biopharmaceutics Classiﬁcation System
lass II and class IV drugs) is usually poor because they slowly dis-
olve in the gastro-intestinal track. One of the strategies that can be
pplied to increase the dissolution rate is the production of a solid
ispersion that is composed of a hydrophilic carrier in which the
rug is ﬁnely dispersed. When this soluble carrier dissolves rapidly,
he poorly soluble drug is hydrated faster, resulting in faster disso-
ution. Inulin has been used to produce solid dispersions of various
oorly soluble drugs (Srinarong, Faber, Visser, Hinrichs, & Frijlink,
009; van Drooge, Hinrichs, & Frijlink, 2004a; Van Drooge et al.,
004b; Visser et al., 2010). Solubility of inulin is much better than
hese drugs and is dependent on the molecular weight of inulin,
ith smaller inulins having a higher solubility (Wada, Sugatani,
erada, Ohguchi, & Miwa, 2005).
Dissolution behavior of solid dispersion tablets made of
iazepam in inulin was signiﬁcantly better than those based on dis-
ersions with disaccharides like sucrose or trehalose (Van Drooge
t al., 2004a). It was found that the dissolution rate of the disaccha-
ides was extremely high, resulting in supersaturation of diazepam
n the near environment of the dissolving tablet, causing it to subse-
uently precipitate into large crystals with obviously detrimental
onsequences on the release proﬁle. This uncontrolled crystalliza-
ion did not occur for inulin included diazepam, due to its lower
issolution rate (Van Drooge et al., 2004a). Fig. 1 illustrates the dif-
erence in release proﬁles of the sugars and diazepam for trehalose
nd sucrose formulations, and the similar release proﬁles for the
olid dispersions of inulin and diazepam.
However, using fenoﬁbrate as model drug, the dissolution
ehavior of the inulin based solid dispersion tablets at high drug
oad (50 wt%) was poor, probably also due to recrystallization
f the incorporated drug during dissolution. This disadvantage
ould be circumvented by the incorporation of superdisintegrants,
roscarmellose sodium or sodium starch glycolate, in solid disper-
ion (Srinarong et al., 2009). Similar solid dispersion tablets based
n polyethylene glycol 20K and and polyvinylpyrrolidone K30 also
xhibited excellent dissolution behavior, but were outperformed
y those based on inulin after they were stored for 3 months at
0 ◦C/45% RH or 40 ◦C/75% RH (Srinarong et al., 2009). Release of
MC240, a HIV protease inhibitor, was improved both in vitro and
n vivo after oral administration due to incorporation in a solid dis-
ersion of inulin (Visser et al., 2010). Lyophilization of nifedipine
ith relatively low concentrations (up to 10%) of inulin directly
n gelatin capsules increased dissolution rate, but as dissolutionolymers 134 (2015) 418–428
measurements were not carried out under sink conditions the
overall dissolution enhancement was  limited (Crum, Elkordy,
Zarara, & Elkordy, 2013).
Inulin improved the dissolution of irbesartan in a physical
mixture, with gradually increasing dissolution rates with increas-
ing inulin content. Chemically modiﬁed poly(acrylic acid) grafted
inulin was less successful at increasing dissolution behavior for
irbesartan (Fares, Salem, & Khanfar, 2011). Another chemically
modiﬁed form of inulin tested for dissolution rate enhance-
ment is Inutec SP1. It is an inulin with alkyl groups grafted
on primary or secondary hydroxyl groups of the polyfructose
backbone and acts as a polymeric surfactant (Janssens, Van
Humbeeck, & Van den Mooter, 2008; Van den Mooter, Vervoort,
& Kinget, 2003). Itraconazol was  incorporated in a solid dis-
persion of Inutec SP1 via spray drying and hot-stage extrusion.
Even though phase separation was found and part of the itra-
conazol was  crystalline, the dissolution behavior of the solid
dispersion was better than that of itraconazol alone (Van den
Mooter et al., 2003). It was later shown that spray dried itra-
conazol and Inutec SP1 showed no interaction and addition of an
itraconazol compatible polymer was  needed to obtain a molec-
ular dispersion (Janssens et al., 2008). Contrastingly, when solid
dispersions with high drug loads were produced by spray freeze-
drying, Inutec SP1 was  found to have superior dissolution behavior
compared to inulin and polyvinylpyrrolidone (Srinarong et al.,
2011).
Amorphous unmodiﬁed inulin has been shown to be a suitable
ﬁller-binder for tablet production, with chain length dependent dis-
integration time (Eissens, Bolhuis, Hinrichs, & Frijlink, 2002). It was
also possible to produce tablets from freeze-dried inulin formula-
tions, in which case preconditioning of the inulin powder at 45% RH
prior to tableting produced the best tablets (Eriksson et al., 2002).
It was  also possible to make a tablet for sublingual administration
of poorly soluble THC based on a solid dispersion with inulin (Van
Drooge et al., 2004b). For regular delivery to the GI tract, dissolu-
tion of 80% of the drug in around 20–30 min  is normal, whereas
sublingual formulations require a dissolution time of a few min-
utes at the most. The inulin based sublingual formulation showed
complete release within around 3 min.
2.2.1.2. Modiﬁed release. Inulin could be used to alter the release
proﬁle of lysozyme from a hydrophilic multiblock copolymer
aimed at prolonged release, because inulin acted as a pore-former
(Stankovic´ et al., 2013). Some studies have also been published in
which drugs are encapsulated with inulin or chemically modiﬁed
inulin for prolonged release (Poulain et al., 2003; Wu & Lee, 2000).
Acetylation of inulin strongly reduces its solubility (in a buffer of pH
7.4). Additional succinylation can then be used to increase solubilty,
allowing control over solubility and with that the release proﬁle of
microspheres from this material (Wu  & Lee, 2000). Microspheres
of this modiﬁed inulin produced by solvent precipitation showed
a porous interior and different particle size distributions for the
different drugs used (Wu & Lee, 2000). Chymotrypsin containing
microspheres, with a particle size distribution from 0.5 to 4 m,
showed release for up to a week with a release of nearly 70% at the
ﬁrst time point of 24 h. Chlorhexidine containing particles were
signiﬁcantly larger, i.e. 90–130 m,  and showed a similar burst
release, followed by a release rate that was slower than the chy-
motrypsin microspheres (Wu  & Lee, 2000). Overall, the prolonged
release is limited, since most of the drug is released in the initial
burst.
Inulin, inulin acetate (inac) and inulin acetate associated with
1,12-dodecanedicarboxylic acid (inac-dia) were used in the encap-
sulation of serine protease inhibitors using coacervation, producing
particles with a size ranging from 0.5 to 5 m (Poulain et al., 2003).
Inulin and inac microspheres showed a burst release of around
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Fig. 1. Dissolution of tablets prepared from solid dispersions and physical mixtures containing 10% w/w diazepam prepared with different sugars: (a) inulin DP23, (b) inulin
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0% in the ﬁrst minutes of dissolution, with a controlled release
f the rest of the dose over a period of 4 days. Inac-dia displayed
n initial burst release of only 32% after 15 min, but showed an
dditional burst release of around 30% after about 1.5 days due to
rosion, followed by prolonged release similar to the inuline and
nac spheres (Poulain et al., 2003). Another example of controlled
elease with a chemically modiﬁed inulin is the chemical coupling
f inulin to ibuprofen using N,N′-cabonyldiimadazole. Nanoparti-
les consisting of methylprednisolone and this ibuprofen-inulin
ould be produced, providing an interesting combination therapy
or spinal cord injury (Zhang et al., 2014). Lastly, it was  recently
hown that inulin conjugated with diethylenetriamine might be
uitable as a carrier for therapeutic delivery of small interfering
NAs (Sardo et al., 2015).
.2.2. Local drug delivery
.2.2.1. Colon targeting. Chemically modiﬁed inulin was also
pplied in controlled delivery to the colon. The mechanism behind
olon targeting with inulin is based on the fact that inulin is only
igniﬁcantly hydrolyzed by inulinases produced by biﬁdobacte-
ia in the colon and not by the digestive enzymes in the upper
arts of the gastro intestinal tract (Flamm,  Glinsmann, Kritchevsky,
rosky, & Roberfroid, 2001; Roberfroid & Delzenne, 1998; Van den
ooter et al., 2003). This means that gels and coatings of inulin
re not hydrolyzed until these reach the colon where they are fer-
ented, resulting in a colon-speciﬁc release of incorporated drug.
everal reports have described chemically modiﬁed methacrylated
nulin (IN-MA) for colonic targeting (Vervoort et al., 1997; Vervoort,
ombaut, Van den Mooter, Augustijns, & Kinget, 1998). These mod-
ﬁed inulin chains can be covalently cross-linked to each other and
ptionally in combination with other monomers using free-radical
olymerization resulting in the chemical formation of a gel (Maris
t al., 2001).lid dispersion : sugar from physical mixture, : diazepam from physical mixture)
Hydrogel characteristics such as swelling need to be well cho-
sen for controlled release. If the gel swells too much, premature
release will occur. On the other hand to achieve a fast enough
release in the colon, sufﬁcient swelling is needed to allow for inuli-
nase to access and hydrolyze the inulin (Maris et al., 2001; Vervoort
et al., 1998). Finding this balance has been proven difﬁcult, but not
impossible (Maris et al., 2001). Gels which were co-polymerized
with N,N′-bis(methacryloylamino)azobenzene could be degraded
both through breakdown by inulinase as well as reduction of the
introduced azo group by bacterial strains present in the colon
(Stubbe, Maris, Van den Mooter, De Smedt, & Demeester, 2001).
The molecular weight of inulin used is also relevant here, as higher
molecular weight inulins form stronger gels and have higher vis-
cosity, in turn inﬂuencing their hydrogel characteristics (Mensink
et al., 2015).
IN-MA was  used for the colonic delivery of bovine serum albu-
min, with release being mainly dependent on degree of substitution
(DS, deﬁned as the amount of methacryloyl groups per 100 fruc-
tose units) of inulin and concentration of IN-MA used (Van den
Mooter et al., 2003; Vervoort et al., 1998). Two formulations, one
with 27% w/w IN-MA and a DS of 8.1 and another with 22% w/w  IN-
MA and a DS of 12.1 were most promising for colonic delivery (Van
den Mooter et al., 2003). Apart from varying DS and concentration
of polymer, copolymerization with other monomers, either more
hydrophobic or more hydrophilic, could also modify release proﬁles
(Maris et al., 2001). Another approach was to use a two-step chem-
ical modiﬁcation of inulin with ﬁrst methacrylic anhydride (MA),
followed by succinic anhydride (SA) for a pH-sensitive release.
Hydrogels of inuline-MA-SA showed a pH-responsive delivery of
ibuprofen and diﬂunisal (Castelli et al., 2008; Tripodo, Pitarresi,
Palumbo, Craparo, & Giammona, 2005). It was also possible to
incorporate IgG during the formation of an inuline-MA1-SA hydro-
gel, achieving controlled colonic release of the protein (Tripodo,
Pitarresi, Cavallaro, Palumbo, & Giammona, 2009).
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Also several other attempts have been made to combine the
etabolic degradation dependent release of inulin with a pH sen-
itive release, but without chemical modiﬁcation and crosslinking.
ree ﬁlms of inulin with several varieties of Eudragit® were pro-
uced and evaluated for colonic delivery. Combinations of inulins
ith Eudragit RS and RL had more potential for colonic delivery
han combinations of inulin and other Eudragit types (Akhgari,
arahmand, Afrasiabi Garekani, Sadeghi, & Vandamme, 2006). An
xample of a tablet formulation for the delivery of aceclofenac to
he colon that has been shown to be successful in an in vivo study
s based on a combination of the pH independent Eudragit® RS100
nd inulin (Sharma & Pathak, 2013).
Recently some non-gel colonic delivery systems based on mod-
ﬁed inulin have been described. Inulin chemically bonded with
innamate was used to form drug containing vesicles for colonic
argeting. The cytostatic methotrexate was successfully encapsu-
ated in these inulin cinnamate vesicles. However, this system
howed a methotrexate release of 30–40% in 24 h even in the
bsence of inulinase (López-Molina et al., 2015). This is undesirable
or a cytostatic agent. Another way to produce inulin particles for
olonic targeting is by electrospraying inulin. To make inulin suit-
ble for electrospraying it was ﬁrst acetylated. Particles containing
ndomethacin produced using this method showed colonic-speciﬁc
elease (by inulinase) in vitro (Jain, Sood, Bora, Vasita, & Katti, 2014).
.2.2.2. Pulmonary delivery. Pulmonary administration of drugs is
ften desirable for pulmonary diseases and it can also be a good
oute for systemic drug administration. The aerodynamic particle
ize (APS) of the inhaled aerosol is of great importance for pul-
onary delivery. An APS of 1–5 m is considered essential to obtain
n adequate lung deposition (Amorij et al., 2007b). Both spray dry-
ng and spray-freeze drying can be used to produce particles with a
road APS distribution, allowing targeting of the airways. As men-
ioned in Section 2.1.2, inulin containing formulations have been
sed to stabilize a vaccine and other proteins during spray drying
nd spray-freeze drying.
A spray-freeze dried inﬂuenza subunit vaccine stabilized by
nulin was suitable for inhalation and induced systemic, mucosal,
umoral and cell-mediated immune responses in mice after pul-
onary administration (Amorij et al., 2007b). Inhaled spray dried
nd spray-freeze dried inﬂuenza subunit vaccines formulations
nduced higher serum IgG titers than intramuscular administration
Saluja et al., 2010). Inﬂuenza whole inactivated virus vaccine spray
reeze-dried with inulin was also safe and efﬁcient for pulmonary
mmunization (Audouy et al., 2011). Combined with the improved
torage stability pulmonary administration of inulin stabilized dry
owder inﬂuenza vaccines seems promising (Audouy et al., 2011;
aluja et al., 2010). Inulin is thus a suitable stabilizer for dry pow-
er formulations of vaccines for pulmonary administration (Tonnis,
exmond, Frijlink, de Boer, & Hinrichs, 2013).
Spray freeze-drying of acyl-homoserine lactone acylase PvdQ,
n enzyme that can be used in the treatment of Pseudomonas
eruginosa infections, with either trehalose or inulin produced
table formulations. The powder particles had an average aerody-
amic diameter of ∼1.8 m,  indicating they would be suitable for
nhalation and might be used in the treatment of chronic infections
n cystic ﬁbrosis patients (Wahjudi et al., 2013). Another exam-
le of a therapeutic spray-freeze dried with inulin is cyclosporine
, which might be used to prevent allograft rejection for lung
ransplant patients (Zijlstra et al., 2009b). Using spray-drying, an
nulin-based formulation of rhDNase was produced with a mass
ean aerodynamic diameter of 2.3 m,  making it a suitable thera-
eutic for patients with cystic ﬁbrosis (Zijlstra et al., 2009a). Lastly,
nulin-stabilized spray freeze-dried particles containing THC were
lso suitable for inhalation (Van Drooge et al., 2005).olymers 134 (2015) 418–428
2.3. Physiological and disease-modifying effects
2.3.1. Systemic
2.3.1.1. Vaccine adjuvant. Apart from being a suitable stabilizer of
vaccines, several papers have reported an adjuvant role of inulin in
obtaining an immune response upon vaccination. Mostly the crys-
talline types of inulin, - and -inulin, which are virtually insoluble
at 37 ◦C, were used. These crystalline forms consist of inulin with a
relatively high molecular weight, the more soluble  and  forms
also contain lower molecular weight inulin fractions (Cooper &
Carter, 1986a). More information on the different subtypes of crys-
talline inulin can be found in the ﬁrst part of this review (Mensink
et al., 2015). It was shown that -inulin enhances both humoral
and cell-mediated immune responses in various animal models for
a wide variety of antigens, making it a very interesting adjuvant
for vaccines (Cooper & Steele, 1988; Silva, Cooper, & Petrovsky,
2004). Cooper and Carter (1986b) reported -inulin speciﬁcally
activates the alternative complement pathway, whereas the more
soluble isoforms of inulin,  and , were found to be biologically
inactive and even hindered pathway activation by -inulin. The
-inulin isoform had not been discovered at that time, but most
likely acts as an adjuvant according to the same mechanism as
-inulin.
It was found that -inulin was more immunoactive than -
inulin (Cooper & Petrovsky, 2011). Thus far, it has for example
been applied to enhance the potency of a trivalent human sea-
sonal inﬂuence vaccine in mice (Honda-Okubo, Saade, & Petrovsky,
2012), split-virion H5N1 inﬂuenza in ferrets (Layton et al., 2011), a
pulmonary formulation of whole inactivated H1N1 inﬂuenza vac-
cine in mice (Murugappan, Frijlink, Petrovsky, & Hinrichs, 2015)
and hepatitis B in mice, guinea pigs and humans (Gordon, Kelley,
Heinzel, Cooper, & Petrovsky, 2014; Saade, Honda-Okubo, Trec, &
Petrovsky, 2013). It was  also shown that co-administration of -
inulin with inactivated H1N1 inﬂuenza vaccine achieved a better
immune response in pregnant mice, both for the mother and the
pups (Honda-Okubo, Kolpe, Li, & Petrovsky, 2014).
In contrast to the above, Kumar and Tummala (2013) have
reported that it is possible to use soluble inulin for both vaccine
stabilization and as an adjuvant. They developed soluble inulin
microparticles which they loaded with ovalbumin and achieved
a robust immune response, outperforming antigens adjuvated by
traditionally used aluminum salts. It would be interesting to see
further research to conﬁrm that soluble inulin can also be an adju-
vant and if conﬁrmed, further investigation into the mechanism
behind turning soluble inulin into an adjuvant.
2.3.1.2. Kidney function. A widely established application of inulin
is as a diagnostic for kidney function testing, for this application
inulin is intraveneously injected. Inulin is highly suitable for this
application because it is distributed over the extracellular volume
only and it is not metabolized. Furthermore it is only excreted via
glomerular ﬁltratrion and not resorbed by renal tubules. This makes
it the most accurate substance for determination of glomerular ﬁl-
tration rate (The Editors of Encyclopaedia Brittanica, 2015). The
test can be executed by administering inulin as a bolus or con-
stant infusion and measured concentrations of inulin in both urine
and plasma can be used for the determination of the ﬁltration
rate (Orlando, Floreani, Padrini, & Palatini, 2002). Because inulin
is ﬁltered out freely because it is relatively small, the excretion
rate is directly proportional to the glomerular ﬁltration rate (The
Editors of Encyclopaedia Brittanica, 2015). As the kidneys do resorb
water, the ratio between the concentrations of inulin in the tubu-
lar ﬂuid plasma can be used to determine water resorption in
the kidney (Feher, 2012). However, a drawback of this method
is the detection of inulin in biological matrices (The Editors of
Encyclopaedia Brittanica, 2015). Several analytical techniques have
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een described in literature, but care should be taken in compar-
ng results from different analytical methods as differences are not
lways negligible (Delanaye et al., 2012).
.3.2. Gastro-Intestinal tract
.3.2.1. Constipation. Inulin is widely used as a dietary ﬁber and
rebiotic in so-called functional foods. These uses are worth men-
ioning in this context, but are not pharmaceutical applications and
e will thus sufﬁce by referring to some reviews on this topic.
lamm et al. (2001) reviewed inulin as a dietary ﬁber, Kolida, Tuohy,
nd Gibson (2002) made a comprehensive overview of the prebi-
tic effects of inulin and oligofructose and lastly Kelly (2008, 2009)
roduced an extensive two-part review about inulin-type prebi-
tics also in relation to some physiological effects. Nutrition can
e used to provide health beneﬁts by modiﬁcation of gut micro-
ial ﬂora (Flint, Scott, Louis, & Duncan, 2012). In fact, inulin’s effect
n gut ﬂora and gut mobility has been linked to a variety of ben-
ﬁcial effects, both local and systemic (Meyer, Bayarri, Tárrega, &
ostell, 2011). Inulin, in particular high molecular weight inulin,
ncreased stool frequency and can thus be used against constipation
Den Hond, Geypens, & Ghoos, 2000). It has been shown to improve
tool frequency in formula fed newborns, creating a gut microbiota
loser to that associated with breastfeeding (Closa-Monasterolo
t al., 2013). Inulin was also able to relieve constipation in elderly
atients, indicating that the stool promoting effect of inulin is
resent for all ages (Marteau et al., 2011).
.3.2.2. Inﬂammatory bowel disease & colon cancer. Oral admin-
stration of inulin has been reported to achieve both local and
ystemic immune modulation. A review of the supporting evidence
oncluded that the local immunomodulatory effect is apparent, but
ystemic effects are less substantiated (Seifert & Watzl, 2007). The
ocal effect is possibly indirect through the prebiotic action of inulin,
timulating growth of beneﬁcial bacteria in the gut (Guarner, 2005;
alyani Nair, Kharb, & Thompkinson, 2010). In a later in vitro study,
t was found that inulin also possesses direct signaling capacity
n human immune cells, mainly through the toll-like receptor 2
Vogt et al., 2013). It is conceivable that these local effects could be
eneﬁcial to patients suffering from inﬂammatory bowel disease
nd irritable bowel syndrome (Leenen & Dieleman, 2007). Thus far,
nvestigations with small numbers of patients have reported mixed
esults in this regard and there is thus a need for further investiga-
ion of this potential application of inulin (Kelly, 2009; Roberfroid,
007).
Inulin was able to reduce chemically induced pre-neoplastic
esions or tumors in the colon of mice and rats (Pool-Zobel, 2005;
erma & Shukla, 2013). Long chain inulins were more potent than
maller chain inulins in this sense. This reduction was  associated
ith the gut ﬂora-mediated fermentation of inulin (Pool-Zobel,
005). In a recent study in rats, inulin showed to have a bigger pro-
hylactic potential to colon carcinogenesis compared to lactulose
Verma & Shukla, 2013). Inulin reduced cytotoxicity and geno-
oxicity in vitro in human colon adenocarcinoma cells (Adebola,
orcoran, & Morgan, 2013). Again these results seem promising,
ut further clinical research is required to see if these results can
e reproduced in vivo in humans.
. Overview
In this review the pharmaceutical applications of inulin, an
ligosaccharide being increasingly used in food, pharma and other
elds, have been reviewed. The most widely established use of
nulin in pharma is as a diagnostic to determine kidney function.
nulin’s chemical structure makes that it is not metabolized by the
ody and excreted completely via glomerular ﬁltration. Gut micro-
iota, however, are able to metabolize inulin. This makes inulinolymers 134 (2015) 418–428 425
suitable for colon speciﬁc drug delivery and as a prebiotic. There
is some evidence that inulin’s prebiotic characteristics also lead to
health beneﬁts, particularly for patients with inﬂammatory bowel
disease or in prevention of colon cancer. These claims, however,
need further evidence.
Solid dispersions of amorphous inulin can be used to improve
the dissolution behavior of lipophilic drugs. Amorphous inulin was
shown to be a suitable stabilizer for membranes and proteins, pro-
tecting them against drought and elevated temperatures. Inulin has
not yet been used in commercial formulations for this purpose but
as the number of new biopharmaceuticals keeps increasing, it could
be an interesting new stabilizer. In addition, insoluble isoforms of
inulin have an adjuvant effect on the immune response achieved
with several vaccines. Inulin could therefore serve two purposes
as an excipient for vaccines, achieving both stabilization and an
increased effectivity. Overall the uses of inulin are already diverse.
Additionally more and more research is being done with chemi-
cally modiﬁed inulins, making it likely that more applications will
be found for this ﬂexible oligosaccharide.
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